| Autor: |
Basavilvazo-Rodríguez A; IMSS, DF México., Bravo-Rodríguez LM, Carranza-Lira S, Celis-González C, Hernández Marín I, Hernández-Valencia M, López Navarro ME, Alvarado Maldonado Jde D, Armando Montaño J, Moreno Avellán AJ, Vázquez G |
| Jazyk: |
Spanish; Castilian |
| Zdroj: |
Ginecologia y obstetricia de Mexico [Ginecol Obstet Mex] 2012 Jul; Vol. 80 (7), pp. 467-72. |
| Abstrakt: |
Vasomotor symptoms are one of the main reasons for climateric women to consult a physician. Hormone therapy is the first treatment choice, but it is not indicated to all patients. Veralipride is an option for those who cannot or will not try hormone treatment. The Mexican Association for the Study of Climateric (AMEC) assembled an interdisciplinary group of medical experts so that they revised the medical literature on the subject and reached a consensus on veralipride indication, doses, counterindications and safety. The recommendations of the consensus conference on veralipride are: (1) Physicians must be familiar with its indication, side effects, pharmacokinetics and dosage. (2) Patients must be informed on other therapeutical options. (3) Patients' mental and neurological state must be evaluated, in particular to identify movement disorders, extrapyramidal symptoms (tremor or dystonia), anxiety and depression that can be mistaken for climateric symptoms. (4) Any adverse effect associated with the drug must be reported. (5) A random multicenter trial must be carried out in order to identify the frequency and severity of side effects, and (6) Written information on possible health risks when using the drug must be provided. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
